TY - JOUR AU - Sawyers, C. L. PY - 1999 DA - 1999// TI - Chronic myeloid leukemia JO - N Engl J Med VL - 340 UR - https://doi.org/10.1056/NEJM199904293401706 DO - 10.1056/NEJM199904293401706 ID - Sawyers1999 ER - TY - JOUR AU - Lugo, T. G. AU - Pendergast, A. M. AU - Muller, A. J. AU - Witte, O. N. PY - 1990 DA - 1990// TI - Tyrosine kinase activity and transformation potency of bcr-abl oncogene products JO - Science. VL - 247 UR - https://doi.org/10.1126/science.2408149 DO - 10.1126/science.2408149 ID - Lugo1990 ER - TY - JOUR AU - Daley, G. Q. AU - Etten, R. A. AU - Baltimore, D. PY - 1990 DA - 1990// TI - Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome JO - Science. VL - 247 UR - https://doi.org/10.1126/science.2406902 DO - 10.1126/science.2406902 ID - Daley1990 ER - TY - JOUR AU - O'Hare, T. AU - Walters, D. K. AU - Stoffregen, E. P. AU - Jia, T. AU - Manley, P. W. AU - Mestan, J. PY - 2005 DA - 2005// TI - In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants JO - Cancer Res VL - 65 UR - https://doi.org/10.1158/0008-5472.CAN-05-0259 DO - 10.1158/0008-5472.CAN-05-0259 ID - O'Hare2005 ER - TY - JOUR AU - Muller, M. C. AU - Cortes, J. E. AU - Kim, D. W. AU - Druker, B. J. AU - Erben, P. AU - Pasquini, R. PY - 2009 DA - 2009// TI - Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations JO - Blood. VL - 114 UR - https://doi.org/10.1182/blood-2009-04-214221 DO - 10.1182/blood-2009-04-214221 ID - Muller2009 ER - TY - JOUR AU - Hughes, T. AU - Saglio, G. AU - Branford, S. AU - Soverini, S. AU - Kim, D. W. AU - Muller, M. C. PY - 2009 DA - 2009// TI - Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2009.21.8230 DO - 10.1200/JCO.2009.21.8230 ID - Hughes2009 ER - TY - JOUR AU - Cortes, J. E. AU - Kantarjian, H. M. AU - Brummendorf, T. H. AU - Kim, D. W. AU - Turkina, A. G. AU - Shen, Z. X. PY - 2011 DA - 2011// TI - Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib JO - Blood. VL - 118 UR - https://doi.org/10.1182/blood-2011-05-355594 DO - 10.1182/blood-2011-05-355594 ID - Cortes2011 ER - TY - JOUR AU - Cortes, J. E. AU - Kim, D. W. AU - Pinilla-Ibarz, J. AU - Coutre, P. AU - Paquette, R. AU - Chuah, C. PY - 2013 DA - 2013// TI - A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1306494 DO - 10.1056/NEJMoa1306494 ID - Cortes2013 ER - TY - JOUR AU - Redaelli, S. AU - Piazza, R. AU - Rostagno, R. AU - Magistroni, V. AU - Perini, P. AU - Marega, M. PY - 2009 DA - 2009// TI - Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.19.8853 DO - 10.1200/JCO.2008.19.8853 ID - Redaelli2009 ER - TY - JOUR AU - Cortes, J. E. AU - Kantarjian, H. AU - Shah, N. P. AU - Bixby, D. AU - Mauro, M. J. AU - Flinn, I. PY - 2012 DA - 2012// TI - Ponatinib in refractory Philadelphia chromosome-positive leukemias JO - N Engl J Med VL - 367 UR - https://doi.org/10.1056/NEJMoa1205127 DO - 10.1056/NEJMoa1205127 ID - Cortes2012 ER - TY - JOUR AU - Hochhaus, A. AU - Breccia, M. AU - Saglio, G. AU - Garcia-Gutierrez, V. AU - Rea, D. AU - Janssen, J. PY - 2020 DA - 2020// TI - Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors JO - Leukemia. VL - 34 UR - https://doi.org/10.1038/s41375-020-0842-9 DO - 10.1038/s41375-020-0842-9 ID - Hochhaus2020 ER - TY - JOUR AU - Pardanani, A. AU - Lasho, T. L. AU - Laborde, R. R. AU - Elliott, M. AU - Hanson, C. A. AU - Knudson, R. A. PY - 2013 DA - 2013// TI - CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia JO - Leukemia. VL - 27 UR - https://doi.org/10.1038/leu.2013.122 DO - 10.1038/leu.2013.122 ID - Pardanani2013 ER - TY - JOUR AU - Dao, K. T. AU - Gotlib, J. AU - Deininger, M. M. N. AU - Oh, S. T. AU - Cortes, J. E. AU - Collins, R. H. PY - 2020 DA - 2020// TI - Efficacy of Ruxolitinib in patients with chronic Neutrophilic leukemia and atypical chronic myeloid leukemia JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.19.00895 DO - 10.1200/JCO.19.00895 ID - Dao2020 ER - TY - JOUR AU - Maxson, J. E. AU - Gotlib, J. AU - Pollyea, D. A. AU - Fleischman, A. G. AU - Agarwal, A. AU - Eide, C. A. PY - 2013 DA - 2013// TI - Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1214514 DO - 10.1056/NEJMoa1214514 ID - Maxson2013 ER -